Avant Technologies and Ainnova in Talks to Obtain Innovative Technology in Preventative Health Reporting
LAS VEGAS, May 20, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are in talks with an international healthcare innovation company to license or potentially acquire its patented early disease detection technology. If successful, it's a global license or acquisition that has the potential to revolutionize preventive health reporting and to generate correlations for future detection of new diseases without the need for all the patient's data.
Avant and Ainnova continue to grow the footprint and capabilities of their technology portfolio with the goal of being a leader in early disease detection using the Company's signature AIdriven Vision AI technology platform.
Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the Company's aim to continue to add to its portfolio, "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily. We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem.
"To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions."
Avant and Ainnova see the retina as a new vital sign, but also understand that leveraging the results of laboratory tests and basic patient data can all work in concert to provide a comprehensive health report.
Vargas added, "We have already integrated an exclusive license for four algorithms into our Vision AI platform, and we are now in talks to license and potentially acquire an innovative technology that would be a game changer in our industry."
Avant will inform its shareholders of any updates at an appropriate time.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Perimeter Announces Closing of Prospectus Offering
TORONTO and DALLAS, June 3, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (" Perimeter" or the " Company"), a commercial-stage medical technology company, is pleased to announce that it has completed its previously announced prospectus offering (the " Offering") of units of the Company (the " Units") and pre-funded units of the Company. The Offering was completed on a reasonable "best efforts" agency basis pursuant to an agency agreement (the " Agency Agreement") dated May 29, 2025 between the Company and A.G.P. Canada Investments ULC (the " Agent"). Pursuant to the Offering, the Company has issued an aggregate of 10,432,801 Units at a price of $0.30 per Unit (the " Offering Price") for aggregate gross proceeds of $3,129,840. Each Unit is comprised of one common share in the capital of the Company (each a " Common Share") and one Common Share purchase warrant (each a " Warrant"). Each Warrant entitles the holder to acquire an additional Common Share for a period of 60 months, at an exercise price of $0.35. Pursuant to the terms of the Agency Agreement, the Agent was entitled to receive a cash fee equal to 7.0% of the gross proceeds raised under the Offering, and compensation options equal to 5.0% of the aggregate number of Units issued under the Offering (the " Compensation Options"), with a reduced cash commission of 3.5% and Compensation Options equal to 2.5% payable in respect of Units sold to certain purchasers on a president's list. In addition, the Agent will receive no cash commission or Compensation Options with respect to sales to certain insiders of the Company. Each Compensation Option entitles the Agent to buy one Common Share at the same price as the price per Unit under the Offering. The Compensation Options are exercisable until that date which is 36 months following the closing date. The Company intends to use the net proceeds from the Offering to continue the commercialization of its technology, establish clinical evidence and continue product development. The Company also intends to use the net proceeds for working capital and other general corporate purposes. The Company may close additional tranches of the Offering for total gross proceeds of up to $15,000,000 (inclusive of the initial closing). The Offering was completed by way of a short form prospectus dated May 29, 2025 (the " Prospectus"). The Prospectus and the Agency Agreement are available on SEDAR+ at and contain important detailed information about the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the " 1933 Act") and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements of the 1933 Act, and applicable state securities laws. Social Capital, a control person of the Company purchased a total of 115,217 Units under the Offering. The placement to such person constituted a "related party transaction" within the meaning of TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (" MI 61-101"). The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61- 101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the placement as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involved the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61-101). The Company has not filed a material change report more than 21 days before the expected closing of the Offering as the details of the Offering and the participants thereof were only finalized shortly before the closing of the Offering. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, statements regarding the use of proceeds from the Offering and the closing of additional tranches, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Annual Information Form for the year ended December 31, 2024, which is available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. Contacts Stephen Kilmer Investor Relations Direct: 647-872-4849 Email: [email protected] Adrian Mendes Chief Executive Officer Toll-free: 888-988-7465 (PINK) Email: [email protected]
Winnipeg Free Press
2 hours ago
- Winnipeg Free Press
Bruno Fernandes turns down lucrative Al Hilal offer to stay at Man United
MUNICH (AP) — Manchester United captain Bruno Fernandes has turned down a proposed move to Saudi club Al Hilal because he wants 'to play at the highest possible level.' Fernandes confirmed Tuesday that he had received an 'exciting offer' from the Riyadh-based club to switch after what was a disappointing season for United. 'They waited for me to think about my future, because I said only if Manchester thought it was the time to move on, that I'd be willing to do so,' Fernandes said through an interpreter. 'I talked to the gaffer, Ruben Amorim, and at the time he asked me not to go. I then talked to Man United. They said they didn't want to sell me. If I wanted to go, I could, but they didn't need the money, they didn't need to sell me.' Media reports suggested Al Hilal was prepared to pay 100 million pounds ($135 million) to take the 30-year-old Fernandes from United while offering him a wage of 700,000 pounds ($946,000) per week to play for the Saudi Pro League team. 'It was a very exciting offer,' Fernandes said. 'The president of Al Hilal, he was very nice to me. He talked to my manager but then I talked to my wife and as a family we wanted to see what I wanted to do. She asked me, what do you want to do with your future?' Fernandes last year signed a contract extension to stay at Old Trafford until June 2027. This season did not go as planned as the Red Devils failed to qualify for the Champions League after finishing 15th in the Premier League, while it also endured the heartbreak of losing the Europa League final to Tottenham. 'We had goals and we didn't meet them,' said Fernandes, a key figure for United since his arrival in January 2020. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. He said it would have been easy for the family to make the move to Riyadh, and for him to adjust to the team with Portugal teammates Rúben Neves and João Cancelo already playing for Al Hilal. 'I'm used to them, but I want to play at the highest possible level,' he said. 'I want play for major competitions. I know I still can, and I want to be happy doing the thing I love the most. And for better or worse, I'm still very passionate about football. This is how I see football. This is how I see my life and my future, and I'm happy about the decision I made.' Fernandes was speaking as a Portugal player before the team's Nations League semifinal against Germany on Wednesday in Munich. The winner of that game will face either France or Spain in Sunday's final. ___ AP soccer:
Calgary Herald
3 hours ago
- Calgary Herald
Alberta and Ottawa tout a grand bargain on 'decarbonized' oil but some are skeptical
Article content OTTAWA — 'Grand bargain' was the phrase of the day on Parliament Hill after Prime Minister Mark Carney and his provincial counterparts found common ground on oil and gas development. Article content 'If (the Conservatives) were listening to yesterday, there is a grand bargain,' Energy Minister Tim Hodgson boasted to the Opposition benches. Article content Article content 'There is a bargain that the premier of Alberta has signed onto.' Article content Article content Alberta Premier Danielle Smith left Monday's first ministers' meeting with a new deal exchanging oil sands access to coastal waters for massive investments in decarbonization technologies, but experts warn this could be a costly pipe dream. Article content Article content 'I'm worried we're seeing (the first ministers) fall into a trap of wanting to have their cake and eat it too,' said Tim McMillan, a partner at Garrison Strategy and the former head of the Canadian Association of Petroleum Producers. Article content 'Let's call it the grand bargain,' Smith told reporters in Saskatoon, referring to the idea of twinning new pipeline proposals with large-scale decarbonization projects. Article content Carney said Monday that he'd consider fast-tracking a new oil pipeline to the West Coast if it shipped 'decarbonized barrels' to new markets. Article content Article content 'There's real potential there (and), if further developed, the federal government will look to advance it,' said Carney. Article content Article content But McMillan says the devil could be in the details. Article content 'I don't know exactly what they're talking about with decarbonization, but… it may be linked to carbon capture, which does not increase our exports (or) investability,' said McMillan. Article content The Calgary-based Pathways Alliance, a group of six major oil sands producers, has put forward a $16.5-billion decarbonization network that would reroute carbon emissions from nearly two dozen facilities to an underground hub near Cold Lake, Alta.
